WE Initiate Science & Technology Value,
Always for Caring

WESTVAC

Media

Company News Popular Science
2024-01-24

WestVac Biopharma Obtains PIC/S GMP Certification from Mexico
Recently, WestVac Biopharma has received the GMP (Good Manufacturing Practice) certificate from the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico, a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S).
Read More
2024-01-14

Selection of China's Top 10 Advances for 2023 in Medical Biotechnology Announced, WestVac Biopharma/Sichuan University West China Hospital's New COVID-19 Vaccine Successfully Selected
On January 13, 2024, the results of the selection for the top 10 medical biotechnology advances in China for 2023, organized by the China Medicinal Biotechnology Association and the journal "Chinese Medicinal Biotechnology" were announced.
Read More
2023-12-26

Caring for the disaster-stricken area, helping one another in the relief work | WestVac Biopharma wastes no time in supplying the trivalent XBB COVID-19 vaccine to Linxia Prefecture, Gansu Province
When one is in trouble, help comes from all directions. WestVac Biopharma will continue to monitor the latest updates on the disaster and cooperate with the local government to ensure the supply of the XBB COVID-19 vaccine. Natural disasters are ruthless, but people are compassionate. May the disaster end soon, and we pray for the safety of the people in the disaster-stricken area.
Read More
2023-11-23

Coviccine® Trivalent XBB Vaccine Widely Administered! Further Fortifying the National Immune Wall
Recombinant COVID-19 Trivalent Protein Vaccine (Sf9 Cell) - Coviccine® Trivalent Vaccine developed by WestVac BioPharma and Sichuan University West China Hospital has been officially launched in in multiple regions across the country.
Read More
2023-11-20

Breaking news! WestVac BioPharma’s Recombinant COVID-19 Trivalent XBB Protein Vaccine Launched Nationwide
On November 20, 2023, WestVac BioPharma’s Recombinant COVID-19 Trivalent XBB Protein Vaccine(Sf9 Cell)-Coviccine® Trivalent XBB Vaccine has been launched nationwide.
Read More
2023-10-23

The pMVA-1 Lipid Complex for Injection developed by WestVac Biopharm was Granted Patents for Inventions in China, the United States and Japan
In September 2023, pMVA-1 lipid complex for injection, an oncology immune agent (WSK-IM02), independently developed by a team of WestVac Biopharm scientists, has obtained authorization from the United States Patent Office after undergoing patent examination. Together with the previously granted patents in China and Japan, this project has received patent authorizations in China, the United States, and Japan, giving it a leading advantage globally.
Read More
2023-08-28

With the emergence of the COVID-19 EG.5 variant, how can the public protect themselves effectively?
The EG.5 variant is a descendant lineage of XBB.1.9.2 (a sublineage of Omicron) and was first reported in Indonesia on February 17, 2023.
Read More
2023-08-07

All four key indicators of SARS-CoV-2 in the United States have increased, suggesting the early stages of a new wave of the pandemic
In July 2023, according to data from the Centers for Disease Control and Prevention (CDC) in the United States, four key indicators including monitoring of SARS-CoV-2 virus concentration in wastewater samples, COVID-19 positivity rate, emergency department visits, and hospitalizations have all increased.
Read More
2023-08-01

Breaking News! China National Health Commission Released "Implementation Plan for COVID-19 Vaccination for Key Groups in the Near Future"
To further prepare for the response to the COVID-19 pandemic during the upcoming autumn and winter seasons and ensure the maximum protection of people's lives and health, on July 31, 2023, the Joint Prevention and Control Mechanism of the State Council for Novel Coronavirus Pneumonia issued the "Implementation Plan for COVID-19 Vaccination for Key Groups in the Near Future" (hereinafter referred to as the "Implementation Plan").
Read More
2023-06-08

China Approves the World’s First Vaccine against XBB Descendent Lineages of SARS-CoV-2 for Emergency Use

On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent（XBB.1.5+BA.5+Delta）Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities in China. This is the first COVID-19 vaccine in the world approved for EUA against XBB descendent lineages of SARS-CoV-2. It demonstrates that China is leading the world in the development of COVID-19 vaccines.
Read More
2023-05-17

The First of Its Kind in the World! The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma has been Approved for Clinical Trials by The National Medical Products Administration of China
On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center, Sichuan University against the most recent circulating XBB variants, received the "Drug Clinical Trial Approval" from the National Medical Products Administration of China.
Read More
2023-05-05

Coviccine® --Recombinant COVID-19 Vaccine (Sf9 cell) by WestVac Biopharma is Available for Vaccination in Guizhou
Recently, the Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine® developed by WestVac Biopharma Co., Ltd. and West China Hospital of Sichuan University was launched in Guizhou. As one of the recommended vaccines in the national Immunization Schedule for Second COVID-19 Booster Dose, Coviccine® has excellent broad-spectrum immune protection against multiple mutant strains.
Read More
2023-04-27

Xiaoping DONG: COVID-19 may become a seasonal disease, vaccine research and development needs to be accelerated
At the 2023 National Vaccines and Health Conference held recently, Xiaoping DONG, Chief Expert of Virology of China CDC, gave an in-depth analysis of the progress of COVID-19 prevention and control and the research and application of COVID-19 vaccine, which attracted thousands of online and offline professionals from the industry. All participants benefited a lot from the presentation.
Read More
2023-04-21

WestVac Biopharma Successfully Selected for Global Unicorn Index 2023 for Two Consecutive Years
On April 18, 2023, Hurun Research Institute released the Global Unicorn Index 2023, a ranking of the world’s start-ups founded in the 2000s, worth at least a billion US dollars and not yet listed on a public exchange. WestVac Biopharma Co., Ltd. was one of the listed companies for two consecutive years.
Read More
2023-04-13

WestVac Biopharma Appeared at the 22nd China Biological Products Annual Conference
On April 12, 2023, the 22nd China Biological Products Annual Conference (CBioPC) was grandly opened in Zhuhai. More than 8,000 people attended the conference, including those from government departments, regulatory agencies and industry associations, experts and scholars from biopharmaceutical fields and research institutes at home and abroad, and representatives of enterprises.
Read More
2023-03-28

Coviccine® --Recombinant COVID-19 Vaccine (Sf9 cell) by WestVac Biopharma is Available for Vaccination in Yunnan

Recently, the Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine® developed by WestVac Biopharma Co., Ltd. and West China Hospital of Sichuan University was launched at several vaccination sites in Yunnan. As one of the recommended vaccines in the national Immunization Schedule for Second COVID-19 Booster Dose (fourth dose), Coviccine® has excellent broad-spectrum immune protection against multiple mutant strains.
Read More
2023-03-16

Coviccine® --Recombinant COVID-19 Vaccine (Sf9 cell) by WestVac Biopharma is Available for Vaccination in Beijing

It is reported that Coviccine® has been delivered to the vaccination sites in several districts and counties in Beijing. Local residents eligible for vaccination may inquire information at the nearby site and make an appointment for vaccination.
Read More
2023-02-28

WestVac Biopharma Obtained “Accreditation Certificate of Foreign Drug Manufacturer” in Japan
WestVac Biopharma has recently obtained the “Accreditation Certificate of Foreign Drug Manufacturer” issued by the Ministry of Health, Labour and Welfare of Japan. Despite Japan’s stringent review and regulatory system, WestVac Biopharma has made breakthroughs one after another in the clinical trial application and registration of its COVID-19 vaccine in Japan.
Read More
2023-02-21

Significant Progress Made on the Trivalent Recombinant Protein COVID-19 Vaccine against Subvariants including XBB.1.5 and BA.5 by WestVac Biopharma
Recently, WestVac Biopharma (Guangzhou) Co., Ltd. (hereinafter referred to as "WestVac Biopharma (Guangzhou)") has made significant progress on the development of the trivalent recombinant protein COVID-19 vaccine against the latest prevalent subvariants including XBB.1.5 and BA.5, which is one of the first trivalent recombinant protein vaccines targeting XBB.1.5 worldwide.
Read More
2023-01-20

Clinical Trial Approval Issued for Coviccine® II—Recombinant COVID-19 Vaccine against Variants including Omicron by NMPA
Following the approval of Coviccine®—Recombinant COVID-19 Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd./West China Hospital of Sichuan University for emergency use by the national authority, WestVac Biopharma/West China Hospital of Sichuan University have again made significant progress in the development of COVID-19 vaccine!
Read More
2023-01-13

Rolling Out the 4th Shot! Coviccine® the 1st “COVID-19 Vaccine Booster” Administered in Chengdu
On the morning of January 13, 2023, Coviccine®-Recombinant COVID-19 Vaccine (Sf9 cell) developed by WestVac Biopharma and West China Hospital of Sichuan University was first administered as a sequential booster following 3 doses of inactivated vaccine at the Northern Vaccination Site of Fangcao Community Health Service Centre in Chengdu High-Tech Industrial Development Zone, Sichuan Province.
Read More
2023-01-03

Chongqing Delegation Visited WestVac Biopharma
On December 30th, 2022, the 6th Meeting of the Chongqing-Chengdu Joint Conference to promote the development of the twin-city economic circle was held in Chengdu. In the morning, the Chongqing delegation visited WestVac Biopharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma") accompanied by Academician WEI Yuquan, Chairman of WestVac Biopharma.
Read More
2022-12-15

Good News! WestVac Biopharma Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine Listed in the "Immunization Schedule for Second COVID-19 Booster Dose”
On December 13, 2022, the State Council's Integrated Group of Joint Prevention and Control Mechanism for Response to COVID-19 issued the "Immunization Schedule for Second COVID-19 Booster Dose " (hereinafter referred to as the "Schedule"). The Recombinant COVID -19 Vaccine (Sf9 cell) - Coviccine developed and produced by WestVac Biopharma Co., Ltd. has been listed in the Schedule as the heterologous booster immunization vaccine followed by 3-dose inactivated vaccine.
Read More
2022-12-05

Recombinant COVID-19 Vaccine - Coviccine Developed by WestVac Biopharma/West China Hospital of Sichuan University Approved for Emergency Use
Recently, the Recombinant COVID-19 Vaccine (Sf9 cell) - Coviccine developed by WestVac Biopharma Co., Ltd./West China Hospital of Sichuan University was approved by the relevant state authorities for emergency use.
Read More
2022-09-01

WestVac Biopharma Successfully Selected for Global Unicorn Index 2022 Half-Year Report
On August 30, 2022, Hurun Research Institute released the Global Unicorn Index 2022 Half-Year Report, listing non-listed companies worldwide founded after 2000 and worth more than $1 billion. Among them, WestVac Biopharma Co., Ltd. was successfully listed.
Read More
2022-07-20

WestVac BioPharma Second Generation Recombinant Variant COVID-19 Vaccine Against Omicron and Other Novel Coronavirus Variants Approved for Phase I/II Clinical Trials in Mexico
Recently, the Mexican drug regulatory authority issued a license to approve the Recombinant Variant COVID-19 Vaccine (Sf9 cell) developed by WestVac BioPharma Co., Ltd. and West China Hospital, Sichuan University to carry out phase I/II clinical studies.
Read More
2022-03-19

Yusuf Timol, Minister Counsellor (Economy) of the South African Embassy BEIJING and Others Visited WestVac Biopharma
On March 19, 2022, Mr. Yusuf Timol, Minister Counsellor (Economy) of the South African Embassy BEIJING visited WestVac BioPharma Co., Ltd (WestVac Biopharma), and had a discussion and exchange with the management team of WestVac Biopharma.
Read More
2022-01-10

Experts From Program for Appropriate Technology in Health (PATH) Visited WestVac Biopharma to Guide Related Work
January 6th to 8th, 2022, Yuan Yuan, head of commerce and business development, GAO Guang, senior technical officer, and DONG Haiyan, senior project officer of Shanghai Representative Office, PATH, visited WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma"), carried out a three-day investigation and training work, and the WestVac Biopharma team accompanied the investigation and held discussion exchange.
Read More
2022-01-06

Progress of WestVac Biopharma's COVID-19 Vaccine Has Attracted International Attention and Reported by Many Overseas Authoritative Media
Recently, the progress of the second generation COVID-19 vaccine of WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma") has attracted international media attention, and has been reported by The Associated Press, Asahi Shinbun, Fox News, Agencia EFE and other overseas authoritative media, causing widespread concern in the global society. In just a few days, more than 600 reports were published.
Read More
2021-12-31

To Boost the High-quality Development of Chengdu, WestVac Biopharma Accelerates the Pace of Scientific＆Technological Innovation
In recent years, Chengdu has focused on the construction of the biopharmaceutical track, accelerated and drove the landing and development of a number of high level projects, and promoted the listing of numerous biopharmaceutical companies on the capital market, which has achieved excellent performance and significant development, and boosted high-quality development of Chengdu by allowing more financial resources to be channeled into the real economy.
Read More
2021-12-20

COVID-19 Vaccine Developed by WestVac BioPharma Has Achieved A Significant Progress Against Omicron
In virtue of funding from the national emergency response project for the mutant COVID-19 vaccine, WestVac BioPharma Co., Ltd. has achieved a significant progress in the second generation COVID-19 vaccine against the Omicron mutant strain.
Read More
2021-12-02

WestVac Biopharma has begun to develop a recombinant protein vaccine against Omicron strain
On November 29, in response to the newly emerging COVID-19 variant strain - Omicron, Wei Yuquan, academician of the Chinese Academy of Sciences and chairman of WestVac Biopharma Co.
Read More
2021-11-30

Foundation for Biomedical Research and Innovation at Kobe (FBRI) - SEAKNIT Biotechnology Co., Ltd. Arrived at WestVac Biopharma to Visit and Exchange
On November 29, 2021, Foundation for Biomedical Research and Innovation at Kobe (FBRI) - Chairman LIU Miaomiao of SEAKNIT Biotechnology Co., Ltd.
Read More
2021-11-16

WestVac Biopharma and the Coalition for Epidemic Preparedness Innovations (CEPI) Held a Video Conference on R＆D Progress of the COVID-19 Vaccine
On November 16, 2021, WestVac BioPharma Co., Ltd. and experts from The Coalition for Epidemic Preparedness Innovations (CEPI) held a video conference on R＆D progress of the WestVac Biopharma’s COVID-19 vaccine.
Read More
2021-11-07

ZENG Guang: A Most Powerful Vaccine Combination is Required in China to Form an Immunologic Barrier
On November 6, at the 4th Hongqiao International Health Technology Innovation Forum, the official event of the 4th China International Import Expo (CIIE),
Read More
2021-10-21

Vice Minister ZHANG Yudong of MOST Visited WestVac
In the afternoon of October 20th 2021, ZHANG Yudong, Vice Minister of Science and Technology, LIU Dong,
Read More
2021-10-20

China Life Science and Biotech Development Report 2021 Released in Chengdu
On October 20th, 2021 China Biotech Innovation Conference, a national grand event in biotechnology, was officially opened in Chengdu, Sichuan. Nearly 30 academicians, over 300 leading experts, 1,000 scholars, and representatives of about 20 Fortune 500 multinational pharmaceutical companies and more than 50 well-known domestic and foreign pharmaceutical enterprises gathered in Chengdu to discuss the new development of biotechnology in China.
Read More
2021-10-05

Many Experts Were Invited by WestVac Biopharma to Carry Out GMP Training
From October 3 to 5, 2021, the GMP training conference of Chengdu WestVac BioPharma Co., Ltd. was held in Bio-town, Chengdu.
Read More
2021-09-09

WHO Expert Was Invited by WestVac Biopharma to Visit＆Guide Related Work
From September 7 to 8, 2021, Dr. TANG Yi, an official of the WHO Representative Office in China, was invited by WestVac BioPharma Co., Ltd.
Read More
2021-08-31

The First time in China! The Recombinant COVID-19 Vaccine developed by WestVac and West China Hospital of Sichuan University enters clinical trials in Japan
In August 2021, the Recombinant COVID-19 Vaccine (Sf9 Cell) developed by WestVac Biopharma Co.,Ltd and National Key Laboratory of Biotherapy, West China Hospital of Sichuan University entered clinical trials in Japan.
Read More
2021-07-21

Deputy Commissioner CHEN Shifei of NMPA Visited WestVAc
On the morning of July 21st 2021, CHEN Shifei, Deputy Commissioner of the National Medical Products Administration, HE Xun, Deputy Director-General of Sichuan Medical Products Administration and YU Hui,
Read More
2021-07-18

Academician Wei’s Team Receives WCHSCU Innovation Translational Prize 2021 for Covid-19 Vaccine Phase III Clinical Trial Achievements
On July 18, 2021, West China Hospital of Sichuan University (“WCHSCU”), put into operation at its heartland a translational medicine (TM) complex as TM research infrastructure and a key clinical research facility of provincial and national importance. On the ceremony
Read More
2021-02-25

Shanghai Pharmaceutical etc has invested in westvac, the vaccine R&D and production and immunotherapy cpmmpany
On ​February 25, Westvac had an industrial and commercial change, adding Shanghai Pharmaceutical(601607.SH), Chengdu Yike Investment Management Co., Ltd. and other shareholders. At the same time, the company’s registered capital increased from 10 million yuan to 790 million yuan, an increase of 7800%, according to the data from Tianyancha APP.
Read More
2020-11-25

The total investment of this cooperation exceeded 5.1 billion! Chengdu High-Tech Industrial Development Zone, Shanghai Pharmaceutical and Westvac Biopharma singed cooperation agreements in the research and development of COVID-19 vaccines.
On November 25, the signing ceremony of the cooperation agreement between Chengdu High-Tech Industrial Development Zone, Shanghai Pharmaceutical and Westvac Biopharma(here in after referred to as “Westvac”) was held in Shanghai. The total investment of this cooperation exceeded 5.1 billion yuan.
Read More
2020-11-16

Li Gang,  vice governor of Sichuan Province Government, attended and witnessed the westvac/west china hospital's COVID-19 vaccine R&D entered phase II of clinical trial & westvac company's a-round financing signing ceremony
On November 16, Li Gang, vice governor of Sichuan Province Government, attended and witnessed the signing ceremony.
Read More
2020-11-16

Nearly 300 million yuan securing in round of a financing of westvac for vaccine research and development
On November 16, the investment signing ceremony between Westvac Biopharma, Sichuan Development and Shanghai Pharmaceutical, was held in Chengdu Xiangyu Hotel. Li Weimin, Dean of West China Hospital of Sichuan University, presided over the Westvac signing ceremony.
Read More
2020-08-22

China's first recombinant protein COVID-19 vaccine production line produced by insect cells landed in ChengDu, planning to produce hundreds of millions vaccine per year

On August 22, the Red Star News reporter was informed that the recombinant protein COVID-19 vaccine developed by National Key Laboratory of Biotherapy of West China Hospital of Sichuan University was approved by the State Food and Drug Administration for clinical trials.
Read More
2020-07-20

Westvas has completed nearly 300 million yuan in round a financing & the production base is expected to be completed by the end of the year

Recently, WestVac Biopharma(here in after referred to as Westvac) announced that it has completed A-round of financing of nearly 300 million yuan, led by Sichuan Development, Shanghai Pharmaceutical, West China Hospital and the team of scientists Funding for scientific and technological achievements, this round of financing was mainly used for production line construction and clinical research development.
Read More